

# Fabio M Iwamoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7850065/publications.pdf>

Version: 2024-02-01

42  
papers

3,183  
citations

279798

23  
h-index

315739

38  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4753  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
2	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	30.7	569
3	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
4	Patterns of care in elderly glioblastoma patients. <i>Annals of Neurology</i> , 2008, 64, 628-634.	5.3	177
5	Atypical and anaplastic meningiomas treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012, 109, 187-193.	2.9	155
6	Glioblastoma in the elderly. <i>Cancer</i> , 2009, 115, 3758-3766.	4.1	103
7	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. <i>World Neurosurgery</i> , 2016, 89, 362-367.	1.3	98
8	Primary dural lymphomas: a review. <i>Neurosurgical Focus</i> , 2006, 21, 1-5.	2.3	96
9	Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. <i>Cancer</i> , 2012, 118, 5595-5600.	4.1	95
10	Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 109, 391-397.	2.9	58
11	Prognosis and patterns of care in elderly patients with glioma. <i>Cancer</i> , 2009, 115, 5534-5540.	4.1	51
12	Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 293-298.	2.9	49
13	Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels. <i>PLoS ONE</i> , 2013, 8, e62982.	2.5	49
14	Craniotomy and Survival for Primary Central Nervous System Lymphoma. <i>Neurosurgery</i> , 2019, 84, 935-944.	1.1	46
15	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. <i>World Neurosurgery</i> , 2015, 84, 913-919.	1.3	44
16	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 303-311.	2.9	43
17	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90.	2.9	40
18	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	13.2	39

#	ARTICLE	IF	CITATIONS
19	MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. PLoS ONE, 2014, 9, e114398.	2.5	38
20	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	1.8	28
21	Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in Oncology, 2014, 4, 90.	2.8	25
22	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. Journal of Neuro-Oncology, 2017, 132, 189-197.	2.9	25
23	Primary Brain Tumors in the Elderly. Current Neurology and Neuroscience Reports, 2010, 10, 252-258.	4.2	23
24	An Update on Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America, 2006, 20, 1267-1285.	2.2	21
25	Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection. Archives in Cancer Research, 2016, 4, .	0.3	18
26	Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Practical Radiation Oncology, 2016, 6, 306-314.	2.1	17
27	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
28	Immunotherapy Against Gliomas: is the Breakthrough Near?. Drugs, 2019, 79, 1839-1848.	10.9	10
29	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. British Journal of Neurosurgery, 2020, 34, 690-696.	0.8	10
30	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. Journal of Neurosurgery, 2020, 132, 1667-1672.	1.6	10
31	Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro-Oncology, 2015, 17, 174-176.	1.2	6
32	Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. Neurology, 2022, 98, .	1.1	6
33	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. Clinical Breast Cancer, 2022, 22, e457-e462.	2.4	6
34	Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. Journal of Immunotherapy, 2022, 45, 254-262.	2.4	6
35	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€” Authors' reply. Lancet Oncology, The, 2017, 18, e709-e710.	10.7	5
36	ATIM-34. RATES AND OUTCOMES OF COMBINATION TUMOR TREATING FIELDS AND IMMUNOTHERAPY IN AÂˆGLIOMA COHORT. Neuro-Oncology, 2016, 18, vi25-vi25.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Primary Central Nervous System Tumors in the Aging Population. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013, 2, 182-187.	0.7	0
38	RTHP-37. RATES AND IMPACT OF COMPLIANCE WITH TUMOR TREATING FIELDS THERAPY IN AÂGLIOMA COHORT. <i>Neuro-Oncology</i> , 2016, 18, vi182-vi182.	1.2	0
39	ATIM-07. STUDY OF PEMBROLIZUMAB, TUMOR TREATMENT FIELDS (OPTUNEÂ®) AND TEMOZOLOMIDE FOR OLDER SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi27-vi27.	1.2	0
40	INNV-06. FACTORS INFLUENCING RECEPTIVITY TO CLINICAL RESEARCH IN AN URBAN NEURO-ONCOLOGY PRACTICE. <i>Neuro-Oncology</i> , 2018, 20, vi139-vi139.	1.2	0
41	QOLP-05. THE EFFECT OF RESILIENCE ON QUALITY OF LIFE IN PATIENTS WITH HIGH GRADE GLIOMAS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2018, 20, vi215-vi215.	1.2	0
42	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii47-ii48.	1.2	0